Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)
| Market Cap | 52.60M+64.3% |
| Revenue (ttm) | 4.88M+306.4% |
| Net Income | -30.14M-1.5% |
| EPS | -0.27+70.4% |
| Shares Out | 65.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,372.864 |
| Open | 0.80 |
| Previous Close | 0.81 |
| Day's Range | 0.80 - 0.83 |
| 52-Week Range | 0.45 - 3.87 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 15.67(+1845.86%) |
| Earnings Date | Nov 5, 2026 |
Rani Therapeutics Holdings, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 2 insiders in the last 90 days.
About RANI
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$RANI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RANI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RANI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RANI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RANI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RANI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RANI
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.11M |
| VXFVanguard Extended Market ETF | $712.83K |
| IBBQInvesco Nasdaq Biotechnology ETF | $6.85K |
| BIBProShares Ultra Nasdaq Biotechnology | $3.30K |
Estimated from each fund’s disclosed top holdings × AUM
RANI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RANI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score